Title

A clinically-feasible protocol for using human platelet lysate and mesenchymal stem cells in regenerative therapies

Date of this Version

3-1-2013

Document Type

Journal Article

Publication Details

Citation only

Warnke, P.H., Humpe, A., Strunk, D., Stephens, S., Warnke, F., Wiltfang, J., Schallmoser, K., Alamein, M., Bourke, R., Heiner, P., & Liu, Q. (2013). A clinically-feasible protocol for using human platelet lysate and mesenchymal stem cells in regenerative therapies. Journal of Cranio-Maxillofacial Surgery, 41(2), 153-161

Access the journal

Copyright © 2013 European Association for Cranio-Maxillofacial Surgery

2013 HERDC Submission. FoR code: 100404;110504

ISSN

1010-5182

Abstract

The transplantation of human stem cells seeded on biomaterials holds promise for many clinical applications in cranio-maxillo-facial tissue engineering and regenerative medicine. However, stem cell propagation necessary to produce sufficient cell numbers currently utilizes fetal calf serum (FCS) as a growth supplement which may subsequently transmit animal pathogens. Human platelet lysate (HPL) could potentially be utilized to produce clinical-grade stem cell-loaded biomaterials as an appropriate FCS substitute that is in line with clinically-applicable practice. The goal of this study was to investigate whether HPL can be successfully used to propagate human mesenchymal stem cells (HMSCs) seeded on clinically-approved collagen materials under clinically-applicable conditions using FCS as a control.

This document is currently not available here.

Share

COinS
 

This document has been peer reviewed.